Literature DB >> 11462032

Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes.

C Balagué1, F Noya, R Alemany, L T Chow, D T Curiel.   

Abstract

Replication-competent adenoviruses are being investigated as potential anticancer agents. Exclusive virus replication in cancer cells has been proposed as a safety trait to be considered in the design of oncolytic adenoviruses. From this perspective, we have investigated several adenovirus mutants for their potential to conditionally replicate and promote the killing of cells expressing human papillomavirus (HPV) E6 and E7 oncoproteins, which are present in a high percentage of anogenital cancers. For this purpose, we have employed an organotypic model of human stratified squamous epithelium derived from primary keratinocytes that have been engineered to express HPV-18 oncoproteins stably. We show that, whereas wild-type adenovirus promotes a widespread cytopathic effect in all infected cells, E1A- and E1A/E1B-deleted adenoviruses cause no deleterious effect regardless of the coexpression of HPV18 E6E7. An adenovirus deleted in the CR2 domain of E1A, necessary for binding to the pRB family of pocket proteins, shows no selectivity of replication as it efficiently kills all normal and E6E7-expressing keratinocytes. Finally, an adenovirus mutant deleted in the CR1 and CR2 domains of E1A exhibits preferential replication and cell killing in HPV E6E7-expressing cultures. We conclude that the organotypic keratinocyte culture represents a distinct model to evaluate adenovirus selectivity and that, based on this model, further modifications of the adenovirus genome are required to restrict adenovirus replication to tumor cells.

Entities:  

Mesh:

Year:  2001        PMID: 11462032      PMCID: PMC114995          DOI: 10.1128/JVI.75.16.7602-7611.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation.

Authors:  S Bagchi; P Raychaudhuri; J R Nevins
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

2.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

Authors:  J Fueyo; C Gomez-Manzano; R Alemany; P S Lee; T J McDonnell; P Mitlianga; Y X Shi; V A Levin; W K Yung; A P Kyritsis
Journal:  Oncogene       Date:  2000-01-06       Impact factor: 9.867

3.  Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.

Authors:  D C Yu; G T Sakamoto; D R Henderson
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

4.  p21cip1 Degradation in differentiated keratinocytes is abrogated by costabilization with cyclin E induced by human papillomavirus E7.

Authors:  F Noya; W M Chien; T R Broker; L T Chow
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 5.  Human papillomavirus vaccines.

Authors:  F Breitburd; P Coursaget
Journal:  Semin Cancer Biol       Date:  1999-12       Impact factor: 15.707

Review 6.  Replicative adenoviruses for cancer therapy.

Authors:  R Alemany; C Balagué; D T Curiel
Journal:  Nat Biotechnol       Date:  2000-07       Impact factor: 54.908

7.  Concordant induction of cyclin E and p21cip1 in differentiated keratinocytes by the human papillomavirus E7 protein inhibits cellular and viral DNA synthesis.

Authors:  Y Jian; B A Van Tine; W M Chien; G M Shaw; T R Broker; L T Chow
Journal:  Cell Growth Differ       Date:  1999-02

8.  Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.

Authors:  A Lieber; C Y He; I Kirillova; M A Kay
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

9.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.

Authors:  C Heise; T Hermiston; L Johnson; G Brooks; A Sampson-Johannes; A Williams; L Hawkins; D Kirn
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

10.  The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A.

Authors:  W C Phelps; C L Yee; K Münger; P M Howley
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

View more
  11 in total

Review 1.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

2.  Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses.

Authors:  Hong Jiang; Ramon Alemany; Candelaria Gomez-Manzano; Diana R Medrano; Michael G Lemoine; Melissa V Olson; Marta M Alonso; Ok-Hee Lee; Charles C Conrad; W K Alfred Yung; Juan Fueyo
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

3.  Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.

Authors:  Christopher J LaRocca; Joohee Han; Amanda O Salzwedel; Julia Davydova; Mark C Herzberg; Rajaram Gopalakrishnan; Masato Yamamoto
Journal:  Oral Oncol       Date:  2016-03-18       Impact factor: 5.337

4.  Activation of adenovirus early promoters and lytic phase in differentiated strata of organotypic cultures of human keratinocytes.

Authors:  Francisco Noya; Cristina Balagué; N Sanjib Banerjee; David T Curiel; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 5.  Gene therapeutic approaches for medullary thyroid carcinoma treatment.

Authors:  Matthias Drosten; Brigitte M Pützer
Journal:  J Mol Med (Berl)       Date:  2003-06-14       Impact factor: 4.599

Review 6.  Current developments in adenovirus-based cancer gene therapy.

Authors:  Daniel T Rein; M Breidenbach; David T Curiel
Journal:  Future Oncol       Date:  2006-02       Impact factor: 3.404

Review 7.  Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy.

Authors:  Christian Bressy; Eric Hastie; Valery Z Grdzelishvili
Journal:  Mol Ther Oncolytics       Date:  2017-03-21       Impact factor: 7.200

Review 8.  Three-dimensional tumor cell cultures employed in virotherapy research.

Authors:  Linus D Kloker; Can Yurttas; Ulrich M Lauer
Journal:  Oncolytic Virother       Date:  2018-09-05

Review 9.  Three-dimensional cell culture models for investigating human viruses.

Authors:  Bing He; Guomin Chen; Yi Zeng
Journal:  Virol Sin       Date:  2016-10-27       Impact factor: 4.327

Review 10.  Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses.

Authors:  Giacomo G Vecil; Frederick F Lang
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.